Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.59 |
| ▸ | HRH2 | P25021 | 2/20 | 0.47 |
| ▸ | PTAFR | P25105 | 6/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7900432 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL7900342 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL7900325 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL7902070 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL7900515 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL7898798 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL7900528 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL7902060 | 0.90 | HRH4 (0.54) | HRH4HRH2HRH1P2RX7 | |
| SCHEMBL504616 | 0.89 | HRH4 (0.51) | HRH4HRH2PTAFRHRH1P2RX7 | |
| SCHEMBL3533799 | 0.83 | NAMPT (0.43) | HRH4PTAFRADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | claimed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | claimed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | claimed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | claimed |
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | claimed |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2012-02-02 | — | — | US | disclosed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | disclosed |
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | disclosed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | disclosed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | disclosed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | disclosed |
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | DAO, AOC1, SIGMAR1 | HRH4 159/4885HRH2 196/4885PTAFR 4057/4885 |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | DAO, CCNY, CBR1 | HRH4 57/4885HRH2 42/4885PTAFR 4058/4885 |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | PLPBP, PYGL, QDPR | HRH4 1716/4885HRH2 997/4885PTAFR 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.